BPC-157

See my Evidence Standards for how I grade the research below.

What It Is

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a 15-amino-acid fragment, sequence GEPPPGKPADDAGLV, derived from a protective protein found in human gastric juice. It's been studied since the early 1990s, primarily by one research group at the University of Zagreb, and has built a reputation as a tissue-repair agent across gut lining, tendon, ligament, and muscle in animal models (Józwiak et al., 2025).

The preclinical literature describes several overlapping mechanisms rather than one clean pathway. I separate what's directly confirmed against a primary source from what simply gets repeated often below, because a pathway being real in a rat model isn't the same thing as it being clinically meaningful in a person.

The Mechanisms, Pathway by Pathway

Hsieh MJ, Liu HT, Wang CN, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." Journal of Molecular Medicine (Berl). 2017;95(3):323-333. PMID: 27847966. In ischemic hind-limb muscle and cultured human vascular endothelial cells, BPC-157 increased vessel density and blood flow recovery, and the effect tracked with increased expression and internalization of VEGFR2, the receptor that mediates angiogenic signaling, followed by downstream Akt and eNOS activation. This study found increased VEGFR2 expression and internalization, not increased VEGF-A itself, a meaningfully different claim than the "upregulates VEGF" language that circulates in patient-facing material, including an earlier version of this page.

Rat and Human Endothelial Cell Models Endpoint: VEGFR2 Expression/Internalization, Angiogenesis

Hsieh MJ, Lee CH, Chueh HY, et al. "Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway." Scientific Reports. 2020;10:17078. PMID: 33051481. A separate study identified activation of endothelial nitric oxide synthase through a Src-Caveolin-1 pathway, with measurable effects on vessel tone within 30 minutes of exposure. This is mechanistically distinct from the VEGFR2 pathway above, not a restatement of it. A frequently repeated claim, that BPC-157 selectively favors eNOS while suppressing the inflammatory iNOS isoform, is more specific than what this study actually establishes, and I could not confirm it against a primary source.

Ex Vivo / Cell Model Endpoint: eNOS Activation via Src-Caveolin-1, Vessel Tone

Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology (1985). 2011;110(3):774-780. PMID: 21030672. In cultured rat Achilles tendon fibroblasts, BPC-157 increased phosphorylation of FAK and paxillin in a dose-dependent manner, along with increased F-actin formation and faster cell migration and spreading, the proposed cytoskeletal mechanism behind its tendon-healing effects. This is ex vivo cell-culture data from rat tissue, not a systemic effect demonstrated in a living animal or a person.

Rat Achilles Tendon Fibroblast Culture Endpoint: FAK/Paxillin Phosphorylation, Cell Migration

Chang CH, Tsai WC, Hsu YH, Pang JHS. "Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts." Molecules. 2014;19(11):19066-19077. A separate in vitro study, same tendon-fibroblast model, different endpoint: BPC-157 dose- and time-dependently increased growth hormone receptor expression at both the mRNA and protein level, and adding growth hormone to BPC-157-treated fibroblasts increased proliferation further through downstream JAK2 signaling. This is a third distinct mechanistic thread, alongside the cytoskeletal effect above, again demonstrated in cultured cells, not in a living animal or a human.

Rat Tendon Fibroblast Culture Endpoint: GH Receptor Expression, JAK2 Signaling

Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. "Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review." HSS Journal. 2025;21(4):485-495. PMID: 40756949. This systematic review reported decreased COX-2 gene expression, decreased myeloperoxidase activity, and decreased IL-6 and TNF-alpha across multiple animal models, alongside modulation of dopamine and serotonin signaling in separate studies. A related claim circulating in patient-facing material, that BPC-157 raises IL-10 and suppresses NF-kB activity specifically, goes further than this review actually documents, and I could not confirm it against a primary source.

Systematic Review, Animal Models Endpoint: COX-2, MPO, IL-6, TNF-alpha Reduction

Two more mechanisms get cited often and deserve the same treatment as the pathways above. A gut-barrier mechanism, involving tight-junction proteins that seal the intestinal lining, is frequently offered as the explanation for BPC-157's oral activity. BPC-157's acid stability and GI-protective effects in animal models are well established in the broader literature, but I could not confirm the specific tight-junction-protein mechanism against a primary source. A growth-hormone-receptor and IGF-1 sensitization pathway, often cited as the rationale for combining BPC-157 with growth hormone secretagogues, falls into the same category: plausible, commonly repeated, and unconfirmed here.

Several of these pathways converge on the same underlying process: new blood vessel growth. That makes angiogenesis stimulation a theoretical concern in active malignancy or any condition where angiogenesis suppression is clinically indicated. This is a class-level caution that applies to other regenerative peptides with similar proposed mechanisms, not something unique to BPC-157, and it's one of the first things I ask about before either BPC-157 or PDA is on the table for a patient.

Beyond the specific mechanisms above, a substantial body of preclinical (animal model) research, largely from the same University of Zagreb research group over several decades, reports BPC-157 effects across gastric ulcer healing, inflammatory bowel disease models, tendon and ligament injury, muscle injury, bone fracture healing, and nerve injury in rodents. This is a large and consistent preclinical literature, and I think it's a real, encouraging signal. Relatively few independent research groups outside the discovering lab have published on this compound, and that concentration matters when judging how independently replicated these preclinical findings actually are.

Evidence Base Quality

Józwiak M, Bauer M, Kamysz W, Kleczkowska P. "Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review." Pharmaceuticals. 2025;18(2):185. PMID: 40005999. This literature and patent review quantifies the single-lab concern directly: a PubMed search retrieved more than 190 articles containing "BPC 157," of which over 80% listed Predrag Sikiric or Sven Seiwerth as first or senior author. This review, and a subsequent published exchange with the Sikiric group defending the compound (Sikiric P, et al. Pharmaceuticals. 2025;18(10):1450, with the original authors' reply at 18(10):1451), also raised a safety consideration worth naming: BPC-157's pro-angiogenic mechanism is, in principle, a plausible tumor-promoting pathway, and the reviewers noted that the "anti-tumor" claims sometimes made for BPC-157 rest on a single, unreplicated 2004 melanoma cell-line experiment, with no published in vivo data showing it inhibits tumor growth or metastasis. This is an open safety question raised in the peer-reviewed literature, not a demonstrated harm and not something I'm speculating about myself.

Narrative Review + Published Scientific Exchange Endpoint: Evidence-Base Quality and Safety Plausibility, Not a Trial Result

A genuinely independent review reaches a similar conclusion. Gwyer D, Wragg NM, Wilson SL. "Gastric Pentadecapeptide Body Protection Compound BPC 157 and Its Role in Accelerating Musculoskeletal Soft Tissue Healing." Cell and Tissue Research. 2019;377(2):153-159. This review, from researchers at Loughborough University in the UK with no connection to the discovering lab, found the preclinical tendon, ligament, and muscle healing data consistently positive across the studies it reviewed, while stating plainly that "the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans." An independent reviewer reaching the same conclusion as the discovering group's own more recent critics is a reassuring sign that this isn't just one side of a dispute. It's the honest state of the evidence.

One claim doesn't hold up. You will frequently see it stated, including in review articles from the discovering research group itself, that BPC-157 was "successful in a Phase II clinical trial for inflammatory bowel disease." I looked for the actual peer-reviewed publication behind that claim, including a registered trial record with a methods and results section, and could not find one. The claim traces back to the same research group's own repeated assertions in review articles and conference abstracts, without an independently verifiable primary trial report behind it. Multiple independent, more recent reviews state plainly that no peer-reviewed randomized controlled trial of BPC-157 in humans has been published for any condition. I'm not saying the trial never happened. I'm saying I could not verify it, and a claim I can't verify doesn't go on this page as though it were established fact.

What Human Data Exists

Lee E, Padgett B. "Intra-articular injection of BPC 157 for multiple types of knee pain." Alternative Therapies in Health and Medicine. 2021;27(4):8-13. PMID: 34324435. This is the closest thing to human outcome data that exists for BPC-157: a retrospective case series of intra-articular BPC-157 injections for knee pain, 12 patients out of 16 total in the series, no control group, no randomization, outcomes assessed by phone-survey self-report at a single private clinic. Until recently this was the entirety of the published human outcome data for BPC-157 itself, and it does not meet the bar of a clinical trial.

Retrospective, Uncontrolled, Single-Center Case Series (n=12) Endpoint: Self-Reported Knee Pain, Phone Survey

He L, Feng D, Guo H, et al. "Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs." Frontiers in Pharmacology. 2022;13:1026182. PMID: 36588717. Rat and dog data on absorption and tissue distribution exists, but pharmacokinetic data in animals establishes how the compound moves through the body, not whether it works clinically in a person.

Rat and Dog Pharmacokinetic Study Endpoint: Absorption, Distribution, Metabolism, Excretion

Venkatakrishnan A, Marwaha A, Gregg CJ, et al. “Rising use of unapproved BPC-157 (‘Wolverine Peptide’) and associated patient-reported outcomes curated from clinical notes.” Preprint, posted 7 September 2026. doi:10.20944/preprints202609.0501.v1. Not peer reviewed. This is by far the largest human dataset on BPC-157, and it is worth being precise about what kind of data it is. Investigators used a large language model to read de-identified clinical notes from a federated United States network, with physician adjudication of each curation step, and identified 1,039 patients with documented BPC-157 use between 2020 and 2026. Quarterly new users rose roughly 33-fold over that period. Mean documented duration of use was 2.2 months, and among the patients where start timing could be established, use preceded the first clinician note about it by an average of 60 days, which is its own useful finding: people are typically two months in before anyone in their care team knows.

On whether it works, the honest reading is that this study cannot say, and its authors say so directly. Among the 354 users where a direction of response was recorded at all, symptomatic improvement in pain, tissue healing or functional return was documented in 79 percent and worsening in 5 percent. The number that belongs beside those: response direction was unavailable for 686 of the 1,039 users, about 66 percent. So the 79 percent describes the third of patients where somebody happened to write an outcome down, which is the classic setup for reporting and confirmation bias. The authors state plainly that these reports cannot establish efficacy or separate BPC-157 from peptide stacking, co-treatments, non-drug interventions, placebo, or selection bias.

The adverse event data are the part with no prior equivalent anywhere in the human literature. Events attributed to the drug were infrequently documented and the authors flag near-certain under-reporting, but what was captured was neuropsychiatric events in 1.4 percent, injection-site hypersensitivity in 1.4 percent, and gastrointestinal events in 1.3 percent, with 93.9 percent physician-adjudicated extraction accuracy for drug-attributed events. That is not a safety profile. It is the first signal of one.

Two caveats on method. Extraction accuracy varied considerably by field, from 96 percent for co-therapies down to 74.4 percent for non-drug interventions, which the authors themselves treat as exploratory. And the work comes from the company whose clinical-note curation platform produced it. Both are reasons to read it as a well-constructed description of how BPC-157 is actually being used, rather than as evidence of what it does.

Preprint · Retrospective LLM-Curated Clinical Notes (n=1,039), No Control Group Endpoint: Documented Use Patterns, Directional Response, Adverse Events

Anecdotal / clinical experience, not yet trial-tested

Patients and providers using BPC-157 in practice commonly report faster recovery from tendon, ligament, and soft-tissue injuries, and improvement in gut-related symptoms. These reports are consistent with the preclinical mechanism, and I think they're worth taking seriously as a signal for where human trials should focus first. The 2026 preprint above is the first attempt to put a denominator under that impression rather than leaving it as an impression, and what it shows is a favorable direction in most patients where anyone recorded a direction, alongside the fact that no direction was recorded in two thirds of them. None of it has been demonstrated in a controlled human trial, so I present it clearly as reported experience, not as established evidence, a bigger gap between anecdote and verified evidence than for most other compounds on this site.

Pentadeca Arginate (PDA): Same Molecule, Different Salt

Pentadeca Arginate and BPC-157 are structurally the same 15-amino-acid peptide. The only proposed difference is the salt used to stabilize it in solution: BPC-157 has conventionally been supplied as an acetate salt, while PDA uses an arginine salt instead. Peptides intended for research or clinical use are almost always manufactured as a salt, meaning the peptide is paired with a counterion that improves its stability and solubility. Swapping salt forms is a legitimate and common strategy elsewhere in pharmacology, and it can genuinely alter solubility, stability, and absorption kinetics without changing the parent molecule's biological target.

This isn't an invented distinction. A patented process for producing arginine (and lysine) salts of this exact pentadecapeptide exists (US Patent 9,850,282), so the underlying chemistry of the swap is real and has prior art. Compounding pharmacies market the arginate form as more stable, which is the stated reasoning for making the swap. That is a reasonable hypothesis given the general principle above, but I have not seen independent, peer-reviewed testing confirming it for this specific formulation. Until that exists, I treat the improved-stability claim as plausible, not proven.

The animal data on BPC-157 is real, extensive, and mechanistically interesting. It hasn't yet been tested in a controlled human trial. The arginate salt form specifically hasn't been tested in anything, animal or human. Those are three separate levels of evidence, worth keeping distinct rather than treating them as interchangeable.

Any patient who competes in a tested sport should know that BPC-157 is on WADA's prohibited list under its S0 category for non-approved substances, and PDA carries that same status since it's the same peptide.

What the Research Doesn't Yet Show

This is where I'm most eager to see real research investment, and BPC-157 is arguably the single best candidate on this site for it: the preclinical mechanism is genuinely well-characterized and consistent across multiple independent pathways, exactly the kind of foundation that should support a well-designed human trial. What doesn't yet exist is a published, peer-reviewed randomized controlled trial of any kind, for any indication, in BPC-157 or in the arginate salt form. Basic questions, effective human dose, optimal route, how long benefits take to appear, and long-term safety, remain genuinely unanswered rather than answered favorably. This isn't a case of a compound that failed human testing. It's a case where rigorous human testing hasn't yet been published at all.

The 2026 clinical-note study makes the reason uncontrolled reports cannot substitute for a trial unusually concrete. Among its 1,039 documented users, 50.5 percent were taking another agent alongside BPC-157, most often testosterone at 17 percent, NSAIDs at 14.7 percent, TB-500 at 12.9 percent and corticosteroids at 11.7 percent, while 15.3 percent were in physical therapy and 12.6 percent had undergone surgery. When half a cohort is on something else and a sixth is recovering from an operation or doing rehabilitation, a favorable report from that cohort cannot be assigned to the peptide. That is not a criticism of the people using it. It is the structural reason this question needs a controlled trial to answer.

Compounded, not FDA-approved for any indication, whether supplied as BPC-157 or as Pentadeca Arginate. Sourcing and availability are discussed at your visit.

Next Step

This page covers mechanism and evidence. Dosing, cycling, and whether either form is appropriate for you are individual clinical decisions made with your provider.

Already a patient? Bring this up at your next 4Ever Young visit. Have a question first?

Linktree DM on Instagram Email Dr. Wilcox